- Home
- ALVR vs MIST Comparison
ALVR vs MIST Comparison
Compare ALVR & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVR
- MIST
- Stock Information
- Founded
- ALVR 2013
- MIST 2003
- Country
- ALVR United States
- MIST Canada
- Employees
- ALVR N/A
- MIST N/A
- Industry
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- ALVR Health Care
- MIST Health Care
- Exchange
- ALVR Nasdaq
- MIST Nasdaq
- Market Cap
- ALVR 87.7M
- MIST 81.5M
- IPO Year
- ALVR 2020
- MIST N/A
- Fundamental
- Price
- ALVR $0.94
- MIST $1.44
- Analyst Decision
- ALVR Sell
- MIST Strong Buy
- Analyst Count
- ALVR 5
- MIST 3
- Target Price
- ALVR $1.00
- MIST $13.00
- AVG Volume (30 Days)
- ALVR 155.6K
- MIST 177.8K
- Earning Date
- ALVR 11-04-2024
- MIST 11-11-2024
- Dividend Yield
- ALVR N/A
- MIST N/A
- EPS Growth
- ALVR N/A
- MIST N/A
- EPS
- ALVR N/A
- MIST N/A
- Revenue
- ALVR N/A
- MIST N/A
- Revenue This Year
- ALVR N/A
- MIST N/A
- Revenue Next Year
- ALVR N/A
- MIST N/A
- P/E Ratio
- ALVR N/A
- MIST N/A
- Revenue Growth
- ALVR N/A
- MIST N/A
- 52 Week Low
- ALVR $0.58
- MIST $1.12
- 52 Week High
- ALVR $2.49
- MIST $3.52
- Technical
- Relative Strength Index (RSI)
- ALVR 69.10
- MIST 42.50
- Support Level
- ALVR $0.74
- MIST $1.41
- Resistance Level
- ALVR $0.91
- MIST $1.53
- Average True Range (ATR)
- ALVR 0.06
- MIST 0.07
- MACD
- ALVR 0.01
- MIST -0.01
- Stochastic Oscillator
- ALVR 94.50
- MIST 26.96
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).